The United States government has initiated two comprehensive trade investigations targeting dozens of nations, marking a significant escalation in global trade policy under the Trump administration. Announced on Wednesday by US Trade Representative Jamieson Greer, these parallel probes examine alleged unfair trade practices related to industrial overproduction and forced labor manufacturing.
The first investigation focuses on structural excess capacity in manufacturing sectors across multiple economies. The European Union, China, Japan, India, Singapore, Switzerland, South Korea, Vietnam, Taiwan, and Mexico are all subject to this scrutiny. Greer indicated the probe would assess whether these nations’ industrial policies create market distortions that disadvantage American producers.
The second investigation, scheduled to launch imminently, will examine approximately 60 trading partners’ enforcement of laws prohibiting imports of goods produced through forced labor. This initiative specifically targets external-facing legislation rather than domestic labor conditions within individual countries.
These actions come weeks after the Supreme Court struck down the administration’s previous global tariff regime, ruling that President Trump had exceeded his authority by invoking emergency economic powers. In response, the administration imposed temporary 10% duties on imports through July 24 while developing more permanent measures.
The current investigations operate under Section 301 of the Trade Act of 1974—the same legal framework previously used to implement tariffs on Chinese imports. Greer emphasized that existing trade agreements with targeted nations would remain ‘independent’ of these probes, though the administration would consider them in final determinations.
While sector-specific tariffs on steel, aluminum, and automobiles remain unaffected by the court ruling, the new investigations could potentially lead to additional penalties. The administration has indicated further country-specific investigations may follow, potentially addressing digital services taxes and pharmaceutical pricing concerns.